FiercePharma

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical ...
FierceBiotech

BioTime, Inc. Announces Completion of ES Cell International Pte Ltd Acquisition

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTIM), a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today ...
FiercePharma

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ...
Business Wire

BioTime Announces Agreement To Acquire Glycosan BioSystems

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has ...
AOL

BioTime, Inc. to Raise $9 Million in Registered Direct Offering

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares ...